ReviewNature reviews. Urology2013
Zinc and zinc transporters in prostate carcinogenesis.
Review in Nature reviews. Urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 3 syntheses or guidelines pooled it, 183 citations in OpenAlex.
- The association between zinc and prostate cancer development: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Comparative study of serum zinc concentrations in benign and malignant prostate disease: A Systematic Review and Meta-Analysis.Scientific reports · 2016Pooled it
- Pooled it
- Molecular Imaging of In Vivo Zinc Distribution Using Nuclear and Magnetic Resonance Imaging.Chemical & biomedical imaging · 2026Review
- Review
- Synthesis, characterization, DFT analysis, molecular docking and anticancer investigations in colorectal carcinoma of a novel pyrazole-hydrazone zinc(II) complex.Scientific reports · 2026Article
- Mitochondrial convergence of ferroptosis and cuproptosis in castration-resistant prostate cancer: From metabolic vulnerabilities to therapeutic targeting.BBA advances · 2026Review
- A bufalin and CRISPR/Cas9 ribonucleoprotein-loaded calcium lactate nanomedicine for pyroptosis/apoptosis and synergistic cancer immunotherapy.Materials today. Bio · 2025Article
- Piperazine-Based Co(III), Ni(II), Cu(II), and Zn(II) Carbodithioate Complexes as Potential Anticancer Agent.ACS omega · 2025Article
- Spatial integration of multi-omics data from serial sections using the novel Multi-Omics Imaging Integration Toolset.GigaScience · 2025Article
- Zinc ions activate AKT and promote prostate cancer cell proliferation via disrupting AKT intramolecular interaction.Oncogene · 2025Article
- Temporal GeneTerrain: advancing precision medicine through dynamic gene expression visualization.Frontiers in bioinformatics · 2025Article
- Organoselenium transition metal complexes as promising candidates in medicine area.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2024Review
- Synthesis, characterization, and crystal structure of hexa-kis-(1-methyl-1Acta crystallographica. Section E, Crystallographic communications · 2024Article
- Structural investigations and antibacterial, antifungal and anticancer studies on zinc salicylaldimine complexes.Future medicinal chemistry · 2024Article
- Modeling Zinc Complexes Using Neural Networks.Journal of chemical information and modeling · 2024Article
- A prognostic and immune related risk model based on zinc homeostasis in hepatocellular carcinoma.iScience · 2024Article
- Chemoproteomic Profiling Maps Zinc-Dependent Cysteine Reactivity.Chemical research in toxicology · 2024Article
- Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets.Signal transduction and targeted therapy · 2024Review
- Dextran-Graft-Polyacrylamide/Zinc Oxide Nanoparticles Inhibit of Cancer Cells in vitro and in vivo.International journal of nanomedicine · 2024Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The healthy human prostate accumulates the highest level of zinc of any soft tissue in the body. This unique property is retained in BPH, but is lost in prostatic malignancy, which implicates changes in zinc and its transporters in carcinogenesis. Indeed, zinc concentrations diminish early in the course of prostate carcinogenesis, preceding histopathological changes, and continue to decline during progression toward castration-resistant disease. Numerous studies suggest that increased zinc intake might protect against progression of prostatic malignancy. In spite of increased dietary intake, zinc accumulation might be limited by the diminished expression of zinc uptake transporters, resulting in decreased intratumoural zinc levels. This finding can explain the conflicting results of various epidemiological studies evaluating the role of zinc supplementation on primary and secondary prostate cancer prevention. Overall, more research into the mechanisms of zinc homeostasis are needed to fully understand its impact on prostate carcinogenesis. Only then can the potential of zinc and zinc transport proteins be harnessed in the diagnosis and treatment of men with prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.